Zacks.com on MSN4h
Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics
The upcoming report from Vertex Pharmaceuticals (VRTX) is expected to reveal quarterly earnings of $3.99 per share, indicating a decline of 5% compared to the year-ago period. Analysts forecast ...
news.crunchbase6h
Funding Is Flush For Startups Focused On Treating Pain
As shares of Boston-based Vertex shot higher on the news of its non-opioid pill, Journavx, we took a look at investment in ...
Trend News Agency9h
Russian pharmaceutical tycoon set to expand co-op with Tajikistan
DUSHANBE, Tajikistan, February 5. Vertex, a Russian pharmaceutical manufacturer, is engaging in discussions with companies in ...